Other News To Note

• Cold Genesys Inc., of Irvine, Calif., reached agreement with the FDA under a special protocol assessment for a proposed Phase II/III pivotal BOND (Bladder Oncolytic virus for Non-muscle invasive bladder cancer Disease) trial of intravesical CG0070 in non-muscle invasive bladder cancer patients with carcinoma-in-situ with Ta and/or T1 who previously failed BCG (Bacillus Calmette-Guerin, a standard intravesical treatment) and refused cystectomy.